Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia
about
OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamiliesDrug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug deliveryModulation of sinusoidal and canalicular elimination of bilirubin-glucuronides by rifampicin and other cholestatic drugs in a sandwich culture of rat hepatocytes.Diagnostic performance of traditional hepatobiliary biomarkers of drug-induced liver injury in the rat.Impact of OATP transporters on pharmacokinetics.Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapyUse of in vitro transporter assays to understand hepatic and renal disposition of new drug candidates.Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination.Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3.Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP)HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphismsRole of OATP transporters in the disposition of drugs.Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibitionBone mineral densities in individuals with Gilbert's syndrome: a cross-sectional, case-control pilot study.HMG-CoA Reductase Inhibitors for Prevention and Treatment of Severe Sepsis.The impact of drug transporters on adverse drug reaction.Organic anion-transporting polypeptides: a novel approach for cancer therapy.Hepatobiliary transporters in drug-induced cholestasis: a perspective on the current identifying tools.Identification of Novel Inhibitors of Organic Anion Transporting Polypeptides 1B1 and 1B3 (OATP1B1 and OATP1B3) Using a Consensus Vote of Six Classification Models.Validation of a total IC50 method which enables in vitro assessment of transporter inhibition under semi-physiological conditions.Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions.Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring?Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir.Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanismPractical preclinical model for assessing the potential for unconjugated hyperbilirubinemia produced by human immunodeficiency virus protease inhibitors.Comparison of intestinal absorption and disposition of structurally similar bioactive flavones in Radix Scutellariae.Systems pharmacology modeling of drug-induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters.Atazanavir-bilirubin interaction: a pharmacokinetic-pharmacodynamic model.Gilbert-Meulengracht's syndrome and pharmacogenetics: is jaundice just the tip of the iceberg?Scientific considerations for pharmacoenhancers in antiretroviral therapy.In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia.Extended mathematical model for "in vivo" quantification of the interaction betweeen atazanavir and bilirubin.Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential.Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714.Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs.Identification of novel cell-impermeant fluorescent substrates for testing the function and drug interaction of Organic Anion-Transporting Polypeptides, OATP1B1/1B3 and 2B1.Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition.OATP1B1 POLYMORPHISM IS A MAJOR DETERMINANT OF SERUM BILIRUBIN LEVEL BUT NOT ASSOCIATED WITH RIFAMPICIN-MEDIATED BILIRUBIN ELEVATIONSolute Carrier (SLC) Family Transporters
P2860
Q27001267-D6AFCDF9-BE3A-493A-A8EF-FC67C76B0B4BQ28081272-34DBBEBF-365D-4E67-B33B-BB9816C395A6Q33296074-C134D4BF-8E97-4A50-82B4-48E264F00C1FQ33577715-A8CA506F-9FBC-427E-8E6C-3B2BE00FC1D3Q34612244-5D9BBF7F-F998-499A-9CB2-2A98E1DDD765Q35595787-BFE9AF1B-F3E1-4BC2-82D9-1B389FADEA0AQ36544962-DD456D9E-05F5-49EB-9009-79B56EE5380CQ36544966-2653829F-7CA9-4660-8B3C-0FCC8C4990F7Q36645956-8A18EDA3-65FA-438B-9534-E262957A3A8EQ36742673-B18C0D4A-7DC4-4D64-B1CB-49D99EACB07AQ36877910-10C8E602-1594-46EA-9BA8-674073892E3BQ37074085-6AE05D18-3B50-45C8-AC93-B9D3F16B13FDQ37113947-79B169B4-618D-416F-B1B5-39B46C24A00AQ37279800-BAD36E68-0183-45AF-97EC-344353DFA2D7Q37291701-510CE76E-4D0C-41AC-9E6F-DCE3D18FB9FCQ38030483-4B37C215-0180-4563-B64B-4DD83E9252DEQ38075820-F5A15DD6-7628-416C-A0E4-81D2452FE2B6Q38132411-2B68CF7B-CDF8-450C-91B0-6062D5F8FA95Q38192698-4780613A-C89D-4482-968E-73E53513DDD0Q38827713-B470B124-7E21-4449-942D-64DD5F2C9A60Q39408750-525DAF0E-662D-448E-93FD-13ECEF1630B0Q39773779-06ACC579-4B5B-4589-BA01-F0C33E5881A4Q40488073-BC4C3276-8091-4CFB-96A8-31D08C1F8EFCQ41139969-FD7CA50D-4E8F-4F2A-96D1-7697B8A6E2D6Q41589503-27138B02-D886-454C-9BF6-778FF6B8FC5DQ41861090-496C8ABD-17DC-45AE-B4D6-9A9FF33C1342Q41987044-073FC256-14A7-4B8A-8D41-81A757CF2012Q42091235-384B46D5-E0FE-4FC1-971B-60FA55FC7C8CQ42263920-2B5A63B0-134E-496A-8D96-3C870F088CA1Q43195722-898232E6-44B6-402D-A33C-0FEEDF829703Q43635970-F134131C-B159-40F3-A812-00B4D683B960Q43638470-D57EF01C-091D-4164-A148-9311D28320B2Q43699242-A476C16F-1EE9-439D-BB83-125A5D3E1923Q43767845-5C958D51-9AD6-4937-AB86-47A4AAA1F2EEQ46119099-9DBD57B6-E229-46BF-A150-EA317DFC7596Q48092928-695872C9-5ACD-4BE1-BA05-95A22A054201Q49247269-88DD07D8-1B8E-496E-BBA1-6897E61AD8A0Q51696345-066C4C34-4D28-4C64-980E-378C756AC60CQ57500316-F5E2A0FD-6195-4813-9E09-AC774304974FQ57684555-40AE6704-801E-4270-97DA-6873A9C650A9
P2860
Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Inhibition of human organic an ...... rug-induced hyperbilirubinemia
@ast
Inhibition of human organic an ...... rug-induced hyperbilirubinemia
@en
Inhibition of human organic an ...... rug-induced hyperbilirubinemia
@nl
type
label
Inhibition of human organic an ...... rug-induced hyperbilirubinemia
@ast
Inhibition of human organic an ...... rug-induced hyperbilirubinemia
@en
Inhibition of human organic an ...... rug-induced hyperbilirubinemia
@nl
prefLabel
Inhibition of human organic an ...... rug-induced hyperbilirubinemia
@ast
Inhibition of human organic an ...... rug-induced hyperbilirubinemia
@en
Inhibition of human organic an ...... rug-induced hyperbilirubinemia
@nl
P2093
P1476
Inhibition of human organic an ...... rug-induced hyperbilirubinemia
@en
P2093
Jinghai J Xu
Scott D Campbell
Sonia M de Morais
P304
P356
10.1016/J.CBI.2004.08.008
P407
P577
2004-11-20T00:00:00Z